|Bid||33.500 x 9000|
|Ask||33.510 x 9300|
|Day's Range||33.450 - 33.575|
|52 Week Range||29.830 - 37.390|
|PE Ratio (TTM)||28.19|
|Earnings Date||Aug 1, 2017|
|Dividend & Yield||1.28 (3.81%)|
|1y Target Est||37.40|
HCA Healthcare's (HCA) second-quarter earnings are likely to witness equivalent, admission growth and accretion from a number of acquisitions. Commercial business will likely be a dampener.
Johnson & Johnson (JNJ) reported a revenue increase of ~2.9% between 2Q16 and 2Q17. The company’s business is broken down into three business segments: Pharmaceuticals, Consumer Products, and Medical Devices. ...
Merck & Co., Inc.'s (MRK) new products like Keytruda, Zepatier and Bridion are likely to drive sales in Q2. However, headwinds remain in the form genericization of key drugs and increasing competition.